Australian stem cell company Cynata Therapeutics announced that it plans to file an application for regulatory approval within the UK to initiate a Phase 1 clinical trial of its iPSC-derived MSC product CYP-001 in July 2016.
This is a significant announcement, because it will be the world’s first allogeneic iPSC clinical trial.
Cynata’s Cymerus™ technology utilizes iPSCs originating from an adult donor as the starting material for generating mesenchymoangioblast (MCAs), and subsequently, for differentiating the cells into mesenchymal stem cells (MSCs). The outcome is that Cynata can produce MSCs in unlimited quantities, in uniform batches, from a single donor, and at low cost. The company’s lead product produced using the s Cymerus™ technology is CYP-001.